newsfilter
← Latest News
GlobeNewswire·

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathway in ALSP - -